 |
| (Source: SK Bioscience) |
By PatenTrip
SK Bioscience has invalidated a South Korean patent held by Moderna Therapeutics.
In March 2025, the Korean Intellectual Property Trial and Appeal Board (KIPTAB) ruled that Moderna Therapeutics' patent titled "Modified nucleosides, nucleotides, and nucleic acids, and uses thereof" (Registration No. KR2014061) is invalid. Moderna Therapeutics retains the option to challenge the decision by filing a cancellation lawsuit with the Patent Court of Korea.
SK Bioscience initially filed the patent invalidation trial in May 2023. The KIPTAB ruling comes nearly two years after the challenge was first initiated.
The disputed patent relates to modified nucleic acid materials designed to elicit a reduced innate immune response. Such technology is generally associated with gene therapy, mRNA vaccines, and RNA interference (RNAi), where minimizing immune activation can enhance efficacy.
As of the end of September 2024, SK Bioscience's quarterly report did not mention any ongoing patent disputes with Moderna. The report, however, detailed other legal proceedings involving SK Bioscience, including its role as a defendant in patent infringement lawsuits brought by Wyeth LLC and Pfizer Korea, as well as a damages lawsuit with the Korea Disease Control and Prevention Agency (KDCA). Additionally, SK Bioscience has filed a lawsuit against the Korea Trade Commission, seeking to overturn an unfair trade practices ruling.
By PatenTrip
Comments
Post a Comment